71 related articles for article (PubMed ID: 22574973)
1. Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.
Bissantz C; Bohnert C; Hoffmann T; Marcuz A; Schnider P; Malherbe P
J Med Chem; 2012 Jun; 55(11):5061-76. PubMed ID: 22574973
[TBL] [Abstract][Full Text] [Related]
2. Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists.
Blaney FE; Raveglia LF; Artico M; Cavagnera S; Dartois C; Farina C; Grugni M; Gagliardi S; Luttmann MA; Martinelli M; Nadler GM; Parini C; Petrillo P; Sarau HM; Scheideler MA; Hay DW; Giardina GA
J Med Chem; 2001 May; 44(11):1675-89. PubMed ID: 11356103
[TBL] [Abstract][Full Text] [Related]
3. Identification of a critical residue in the transmembrane domain 2 of tachykinin neurokinin 3 receptor affecting the dissociation kinetics and antagonism mode of osanetant (SR 142801) and piperidine-based structures.
Malherbe P; Kratzeisen C; Marcuz A; Zenner MT; Nettekoven MH; Ratni H; Wettstein JG; Bissantz C
J Med Chem; 2009 Nov; 52(22):7103-12. PubMed ID: 19817444
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel NK1/NK3 dual antagonists for the potential treatment of schizophrenia.
Catalani MP; Alvaro G; Bernasconi G; Bettini E; Bromidge SM; Heer J; Tedesco G; Tommasi S
Bioorg Med Chem Lett; 2011 Nov; 21(22):6899-904. PubMed ID: 21974957
[TBL] [Abstract][Full Text] [Related]
5. Molecular cloning, mutations and effects of NK1 receptor antagonists reveal the human-like pharmacology of gerbil NK1 receptors.
Engberg S; Ahlstedt I; Leffler A; Lindström E; Kristensson E; Svensson A; Påhlman I; Johansson A; Drmota T; von Mentzer B
Biochem Pharmacol; 2007 Jan; 73(2):259-69. PubMed ID: 17097619
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).
Giardina GA; Raveglia LF; Grugni M; Sarau HM; Farina C; Medhurst AD; Graziani D; Schmidt DB; Rigolio R; Luttmann M; Cavagnera S; Foley JJ; Vecchietti V; Hay DW
J Med Chem; 1999 Mar; 42(6):1053-65. PubMed ID: 10090788
[TBL] [Abstract][Full Text] [Related]
7. Distribution and pharmacological characterization of primate NK-1 and NK-3 tachykinin receptors in the central nervous system of the rhesus monkey.
Nagano M; Saitow F; Haneda E; Konishi S; Hayashi M; Suzuki H
Br J Pharmacol; 2006 Feb; 147(3):316-23. PubMed ID: 16331282
[TBL] [Abstract][Full Text] [Related]
8. Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.
Malherbe P; Knoflach F; Hernandez MC; Hoffmann T; Schnider P; Porter RH; Wettstein JG; Ballard TM; Spooren W; Steward L
Br J Pharmacol; 2011 Feb; 162(4):929-46. PubMed ID: 21039418
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
[TBL] [Abstract][Full Text] [Related]
10. Mapping the binding pocket of a novel, high-affinity, slow dissociating tachykinin NK3 receptor antagonist: biochemical and electrophysiological characterization.
Malherbe P; Knoflach F; Marcuz A; Bohnert C; Weber M; Knust H; Ratni H; Spooren W; Ballard TM; Bissantz C
Neuropharmacology; 2014 Nov; 86():259-72. PubMed ID: 25107588
[TBL] [Abstract][Full Text] [Related]
11. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.
Sarau HM; Griswold DE; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Webb EF; Martin LD; Legos JJ; Whitmore RG; Barone FC; Medhurst AD; Luttmann MA; Giardina GA; Hay DW
J Pharmacol Exp Ther; 2000 Oct; 295(1):373-81. PubMed ID: 10992004
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 1. Identification of the 4-quinolinecarboxamide framework.
Giardina GA; Sarau HM; Farina C; Medhurst AD; Grugni M; Raveglia LF; Schmidt DB; Rigolio R; Luttmann M; Vecchietti V; Hay DW
J Med Chem; 1997 Jun; 40(12):1794-807. PubMed ID: 9191956
[TBL] [Abstract][Full Text] [Related]
13. Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3.
Leffler A; Ahlstedt I; Engberg S; Svensson A; Billger M; Oberg L; Bjursell MK; Lindström E; von Mentzer B
Biochem Pharmacol; 2009 May; 77(9):1522-30. PubMed ID: 19426690
[TBL] [Abstract][Full Text] [Related]
14. Evidence that the proposed novel human "neurokinin-4" receptor is pharmacologically similar to the human neurokinin-3 receptor but is not of human origin.
Sarau HM; Mooney JL; Schmidt DB; Foley JJ; Buckley PT; Giardina GA; Wang DY; Lee JA; Hay DW
Mol Pharmacol; 2000 Sep; 58(3):552-9. PubMed ID: 10953048
[TBL] [Abstract][Full Text] [Related]
15. Novel triple neurokinin receptor antagonist CS-003 strongly inhibits neurokinin related responses.
Tsuchida H; Takahashi S; Nosaka E; Mukaiyama O; Yamashita M; Morimoto K
Eur J Pharmacol; 2008 May; 586(1-3):306-12. PubMed ID: 18353309
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potent, balanced and orally active dual NK1/NK3 receptor ligands.
Peters JU; Hoffmann T; Schnider P; Stadler H; Koblet A; Alker A; Poli SM; Ballard TM; Spooren W; Steward L; Sleight AJ
Bioorg Med Chem Lett; 2010 Jun; 20(11):3405-8. PubMed ID: 20430616
[TBL] [Abstract][Full Text] [Related]
17. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
[TBL] [Abstract][Full Text] [Related]
18. [Human NK inhibitory and activating receptors that bind to human leukocyte antigens (HLA) regulate NK cells and T cells].
Ikeda H; Coulie PG
Tanpakushitsu Kakusan Koso; 1997 Nov; 42(15):2510-21. PubMed ID: 9391340
[No Abstract] [Full Text] [Related]
19. Modification of the potent peptide FK888 with unusual aminoacids: effects on activity on neurokinin receptors.
Caliendo G; Greco G; Grieco P; Perissutti E; Santagada V; Calignano A; Mancuso F; Novellino E
Farmaco; 1996 Mar; 51(3):197-201. PubMed ID: 8688142
[TBL] [Abstract][Full Text] [Related]
20. Molecular modeling of neurokinin B and tachykinin NK₃ receptor complex.
Ganjiwale AD; Rao GS; Cowsik SM
J Chem Inf Model; 2011 Nov; 51(11):2932-8. PubMed ID: 21913652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
